Galera Therapeutics, Inc. (GRTX): Nasdaq/NYSE listing notice — Galera Therapeutics receives Nasdaq delisting notices; plans to appeal

Galera Therapeutics, Inc.

March 21 notice: failed to meet $50M MVLS and $1.00 bid price for 30 consecutive days.
March 26 notice: failed to meet $15M market value of publicly held shares requirement.
Company will request hearings by March 28 and April 2 deadlines; stay pending outcome.
May request transfer to Nasdaq Capital Market; no guarantee of approval or continued listing.
Common stock (GRTX) expected to remain listed at least until Panel decision.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Galera Therapeutics, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5450(b)(2)(A), 5450(b)(2)(C)

Exact text from the filing

March 26, 2024, the Company received a letter from the Staff indicating that the Company has not regained compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum MVPHS Requirement”), and that, unless the Company requests a hearing before a Panel to appeal Nasdaq’s delisting determination by 4:00 p.m. Eastern Time on April 2, 2024, trading of the Company’s common stock will be suspended at the opening of business on April 3, 2024, and the C

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Galera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-078226

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.